Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors.
Activation markers of blood coagulation and fibrinolysis and several fibrinolytic parameters were determined in arteriosclerotic patients to investigate the relation between extension and main localization of vessel disease, risk factors and disturbances within the blood coagulation and the fibrinolytic system. Indications of an increased intravascular fibrin formation and subsequent fibrinolysis were found in peripheral artery disease (PAD) patients but not in coronary artery disease (CAD) patients. Compared with healthy controls PAD patients had elevated TAT (median: 3.2 ng/ml, 1.5-70 vs. 2.1, 1.2-4.7, p less than 0.005) and D-Dimer (median: 365 ng/ml, range 85-2000 vs. 185, 79-360; p less than 0.0001) plasma levels, whereas TAT (2.4, 1.2-13) and D-Dimer (190, 58-1000) levels of CAD patients were in the normal range. No associations were detected between risk factors of arteriosclerosis (hyperlipidemia, diabetes mellitus, cigarette smoking, hypertension) and the plasma levels of the activation markers TAT and D-Dimer. Independent from risk factors PAD and CAD patients had elevated plasma plasminogen activator inhibitor capacity (PAI cap). Our results provide evidence that 1) increased plasma levels of blood coagulation and fibrinolysis activation markers are not related to risk factors of arteriosclerosis but seem to be unspecifically caused by activation processes on arteriosclerotic vessel wall defects, 2) increased plasma PAI cap found in arteriosclerotic patients is a relatively unspecific phenomenon associated with arterial vessel disease.
Speiser
W
W
Division of Haematology and Blood Coagulation, University of Vienna, Austria.
Speiser
P
P
Minar
E
E
Korninger
C
C
Niessner
H
H
Huber
K
K
Schernthaner
G
G
Ehringer
H
H
Lechner
K
K
D000990:Antithrombin III / Q000378:metabolism; D001161:Arteriosclerosis / Q000097:blood*; D001777:Blood Coagulation / Q000502:physiology*; D003324:Coronary Artery Disease / Q000097:blood; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D010447:Peptide Hydrolases / Q000378:metabolism; D015849:Plasminogen Inactivators / Q000097:blood; D010978:Platelet Factor 4 / Q000378:metabolism; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; D015849:Plasminogen Inactivators; C046193:antithrombin III-protease complex; D001620:beta-Thromboglobulin; C036309:fibrin fragment D; D010978:Platelet Factor 4; D000990:Antithrombin III; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator